Anti-dsDNA, anti-nucleosome and anti-C1q antibodies as disease activity markers in patients with systemic lupus erythematosus

Živković, Vesna; Stanković, Aleksandra; Cvetković, Tatjana; Mitić, Branka; S, Kostić; Nedović, Jovan; Stamenković, Bojana

doi:10.2298/sarh1408431z

Cited by 25 publications

(29 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding the relationship between double positive antibodies and laboratory findings, our study showed that patients with double positive antibodies have a significantly higher disease activity as assessed by ECLAM score, elevated ESR, lower serum albumin and low C3 levels. Our findings parallel those of other authors [38,39].…”

Section: Discussionsupporting

confidence: 93%

Association of anti-nuclesome and anti C1q antibodies with lupus nephritis in an Egyptian cohort of patients with systemic lupus erythematosus

Metwally¹,

Eesa²,

Yacoub³

et al. 2019

Adv Rheumatol

View full text Add to dashboard Cite

Introduction: Anti-nucleosome and anti-C1q antibodies demonstrated an association with the development of glomerulonephritis in systemic lupus erythematosus (SLE). Some investigators have proposed that monitoring anti-C1q and anti-nucleosome antibodies might be valuable for making predictions about lupus nephritis (LN) and assessment of disease activity as a non-invasive biological marker of renal disease. Objectives: The current study was proposed to investigate the presence of anti-C1q and anti-nucleosome antibodies in the sera of Egyptian patients with SLE and their association with LN. Methods: Eighty patients with SLE were included. Patients were classified into, a LN group including 40 cases with active LN (based on the results of renal biopsy and renal SLEDAI≥4) and a non renal SLE group including 40 patients (with no clinical or laboratory evidence of renal involvement that were attributed in the past or present to SLE). They were subjected to full medical history taking, clinical examination, routine laboratory investigations, measurement of antinuclear antibody (ANA), anti-ds DNA, anti-C1q & anti-nucleosome antibodies. Results: Anti-C1q antibody showed a statistically significant association with the presence of vasculitis and nephritis while anti-nucleosome antibody didn't show a significant association with the presence of any clinical features. Double positivity of anti-nucleosome and anti-C1q antibodies showed a statistically significant association with the presence of vasculitis and photosensitivity, high ECLAM score, elevated ESR, low serum albumin and low C3 levels. Conclusion: Serum anti-C1q antibody has a significant association with LN while double positive antibodies have a significant association with vasculitis and low C3 levels in Egyptian patients with SLE.

show abstract

Section: Discussionsupporting

confidence: 93%

Association of anti-nuclesome and anti C1q antibodies with lupus nephritis in an Egyptian cohort of patients with systemic lupus erythematosus

Metwally¹,

Eesa²,

Yacoub³

et al. 2019

Adv Rheumatol

View full text Add to dashboard Cite

show abstract

“…In addition to C1q complement, serum levels of complements C3 and C4 are also decreased in SLE patients [ 24 ]. Therefore, levels of C1q, C3, and C4 and/or the autoantibodies to C1q, dsDNA, and chromatin/nucleosome in serum are important immunological markers in the diagnosis of SLE, particularly for LN disease [ 7 , 10 , 12 , 13 , 24 – 26 ].…”

Section: Introductionmentioning

confidence: 99%

Antibodies against C1q Are a Valuable Serological Marker for Identification of Systemic Lupus Erythematosus Patients with Active Lupus Nephritis

Chi

Shi

et al. 2015

Disease Markers

View full text Add to dashboard Cite

Objective. An early diagnosis of lupus nephritis (LN) has an important clinical implication in guiding treatments of systemic lupus erythematosus (SLE) in clinical settings. In this study, the diagnostic values of circulating autoantibodies to C1q alone or in combination with other markers for accessing active SLE and LN were evaluated. Methods. The diagnostic value of anti-C1q autoantibodies for identification of patients with active SLE disease and LN was evaluated by analyzing the level of anti-C1q antibodies in sera from 95 SLE patients, 40 non-SLE patients, and 34 healthy cohorts. Results. The prevalence of anti-C1q antibodies was significantly higher in patients with SLE (50/95, 52.6%), active SLE (40/51, 78.4%), and LN (30/35, 85.7%) in comparison with non-SLE patient controls, patients with inactive SLE, and non-LN, respectively. A combination of anti-C1q with anti-dsDNA and/or levels of complements C3 and C4 exhibited an increased specificity but a decreased sensitivity for identification of patients with active SLE and LN diseases relative to each of these markers alone. Conclusion. Anti-C1q antibodies were strongly associated with disease activity and LN in SLE patients, suggesting that it may be a reliable serological marker for identification of SLE patients with active LN and active SLE disease.

show abstract

“…A strong association between αC1q ab and active renal disease has been demonstrated [18]. Only nine studies have longitudinal data permitting this specific assessment (including 10,14), although other reports have supported its potential for this use [9,10,12,17]. The present study measured the levels of αC1q ab in a cohort of diagnosed and treated Western Australian SLE patients using a commercial ELISA kit.…”

Section: Introductionmentioning

confidence: 83%

“…In the last decade, the relationship between αC1q ab and clinical profiles in SLE patients, as well as relationships with other laboratory parameters has been investigated. It has been reported by several groups [6,[8][9][10] that the levels of αC1q ab titers are usually significantly higher in SLE patients than healthy controls or non-SLE autoimmune patients. The concentrations of αC1q ab correlate with disease activity and/or severity [6,[8][9][10][11][12][13][14][15][16][17][18][19] as well as with other laboratory parameters including complement protein C3 and/or C4 concentrations, dsDNA ab, proteinuria and the presence of immune complexes [6,8,11,12,[14][15][16][17][18][19].…”

Section: Introductionmentioning

confidence: 97%

Anti-C1Q Antibodies Concentrations by Elisa in Systemic Lupus Erythematosus

Margery-Muir¹,

Wetherall²,

Groth³

et al. 2017

Lupus Open Access

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is an inflammatory disorder in which autoantibodies contribute to impaired apoptosis and clearance of cell debris. Anti dsDNA and anti C1q antibodies have been implicated, as well as complement protein C1q itself. IgG autoantibodies reacting with the collagen-like region of C1q protein (αC1q ab) were quantitated in serum of 56 patients diagnosed with SLE and undergoing treatment for variable periods, together with 33 age/sex-matched controls. Analysis of the results showed optimal sensitivity and specificity of 57% and 91% respectively at a cut-off concentration for positivity of 20 U/ml. The assay is a potentially useful confirmatory test for SLE, but is not suitable as a screening test for SLE with the probability of a positive test and SLE in an individual within a random population of only ≤ 1%. αC1q ab concentrations were detectable in all samples tested with concentrations manifesting no correlation with age and serum C1q levels in SLE patients and a negative correlation with age in controls. The αC1q ab detected by this assay do not react therefore with native C1q. In SLE patients, αC1q ab concentrations correlated with the concentrations of dsDNA antibodies, (p=0.0001) and Creactive protein and inversely with complement component C4 (C4) concentrations (p=0.041). αC1q ab concentrations were not associated with individual therapeutic regimens, but were higher in those patients receiving a combination of three drug therapies and with the presence of renal disease. The diagnostic relevance of this complex autoantibody will require further definition of its antigenic specificities. Lupus

show abstract

Anti-dsDNA, anti-nucleosome and anti-C1q antibodies as disease activity markers in patients with systemic lupus erythematosus

Abstract: Anti-nucleosome and anti-C1q antibodies demonstrated association with SLE and lupus nephritis activity, suggesting their potential usefulness in making predictions about lupus nephritis and assessment of disease activity.

Cited by 25 publications

References 31 publications

Association of anti-nuclesome and anti C1q antibodies with lupus nephritis in an Egyptian cohort of patients with systemic lupus erythematosus

Association of anti-nuclesome and anti C1q antibodies with lupus nephritis in an Egyptian cohort of patients with systemic lupus erythematosus

Antibodies against C1q Are a Valuable Serological Marker for Identification of Systemic Lupus Erythematosus Patients with Active Lupus Nephritis

Anti-C1Q Antibodies Concentrations by Elisa in Systemic Lupus Erythematosus

Contact Info

Product

Resources

About